Life Sciences

Amgen brochure misleading, FDA warns

Pharma Compliance Alert, November 5, 2008

Amgen’s direct-to-consumer patient brochure for Senispar tablets improperly omits and minimizes risks associated with the drug and broadens its uses, according to an FDA warning letter.

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   
    Healthcare Life Safety Compliance
  • Healthcare Life Safety Compliance

    Created exclusively for healthcare facility managers, plant operations professionals, and directors of engineering, this...

  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    A subscription to Medical Environment Update pays for itself by saving you time sorting through complex regulations and...

  • Bloodborne Pathogens Training Video

    Meets OSHA requirements for training employees on the bloodborne pathogens standard!

  • Complete Guide to Lab Safety, 3rd Ed.

    The third edition of this popular resource makes training and compliance easier by consolidating regulations from all...

Most Popular